Navigation Links
Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS)

SWARTZ CREEK, Mich., Oct. 10 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that Teva Neuroscience has selected Diplomat Specialty Pharmacy to be one of only three sites to participate in a large scale, national Therapy Optimization Study for Multiple Sclerosis (TOP MS).

The goal, of the two year TOP MS study, is to examine the benefits of a specialty pharmacy therapy management program on compliance, adherence and patient outcomes. Targeted patient outcomes will include: Relapses, Disability Progression, Quality of Life, and Work and Usual Activity Participation.

"We are honored that Teva Neuroscience selected Diplomat to participate in this study," said Phil Hagerman, President and CEO of Diplomat. "I have no doubt that the TOP MS study will validate the benefits of our patient centric model. When we focus on adherence and tolerance, and offer patients a personalized medication program, we can reduce the frequency and severity of relapses and ultimately improve the quality of life."

"Diplomat Specialty Pharmacy was selected to participate in this study because they have shown a commitment to therapy management in MS that is exemplary among Specialty Pharmacies," said MerriKay Oleen-Burkey, Project Leader for the TOP MS Study at Teva Neuroscience.

"This really is a credit to Diplomat's industry leading MS Navigator program that currently benefits physicians and especially MS patients across the country," said Ken Visser, Diplomat's National Accounts Manager for Multiple Sclerosis. "At Diplomat we maximize therapy adherence by enhancing patient education and prescriber communication. Using our exclusive eNAV(TM) patient care software system, we can electronically record and report our patients' therapy and disease. All of this combined amounts to some of the highest patient adherence numbers in the country."

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is the nation's largest independently held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn's and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Replacement Therapy and Specialty Compounding. The company also specializes in Disease Management programs for Chronic Kidney Disease patients, as well as Home and Out-Patient Infusion. With locations in Flint, Swartz Creek and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

About Teva Neuroscience

Teva Neuroscience is the branded neurological products franchise of Teva Pharmaceutical Industries Ltd. and is responsible for the development, registration and marketing for Teva's branded neurological products in North America. Teva Neuroscience has administrative, commercial marketing, and other leadership functions based in Kansas City, MO at its North American headquarters, as well as a facility in Horsham, PA, home to the company's clinical research activities and regulatory functions, and an office in Montreal, Quebec, headquarters for the company's Canadian presence.

Contact: Ken Visser, National Accounts Manager for Multiple Sclerosis

Phone: 616-242-1082

Fax: 616-454-9095


SOURCE Diplomat Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
3. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
4. U.S. Preventive Medicine Acquires Specialty Disease Management
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
7. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
8. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
10. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
11. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
Post Your Comments:
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
Breaking Medicine News(10 mins):